DCM
BIO icon

Delpha Capital Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Delpha Capital Management’s Portfolio BIO Stock Details BIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-164
Closed -$39K – 245
2017
Q4 		$39K Buy
+164
New +$39.7K 0.04% 416

Other funds holding BIO

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACM
Atlanta Capital Management Atlanta, Georgia $22.5B AUM 9.67% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $84.2B AUM 55.88% 1-Year Est. Return
American Century Companies
American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
TCM
TimesSquare Capital Management New York $6.8B AUM 45.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Delpha Capital Management's BIO Position: Q1 2018 in Review

Delpha Capital Management sold out of Bio-Rad Laboratories Class A (BIO) in Q1 2018, closing a stake of 164 shares — an estimated $39K sold.

Delpha Capital Management first reported a position in BIO in Q4 2017 and held it in 1 quarter. The position peaked at $39K in Q4 2017. 317 funds tracked by Wall St. Rank hold BIO as of Q1 2018.

  • Delpha Capital Management reported no remaining Bio-Rad Laboratories Class A position as of Q1 2018 after selling out during the quarter.
  • Delpha Capital Management sold 164 Bio-Rad Laboratories Class A shares in Q1 2018, an estimated $39K.
  • Delpha Capital Management first reported a position in Bio-Rad Laboratories Class A in Q4 2017 and held it in 1 quarter.
  • Delpha Capital Management's Bio-Rad Laboratories Class A position peaked at $39K in Q4 2017.
  • 317 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q1 2018.

Based on Delpha Capital Management's 13F filing for Q1 2018, filed 11 May 2018.